In September 2022, 72 IPhO student chapters from across the country embarked on a six-month professional journey to create a drug development plan that would bring a theoretical new bladder cancer medicine to market.

Participating teams were asked to cover drug development from many perspectives, including clinical development, medical strategy, regulatory affairs, and marketing. With support from the Bladder Cancer Advocacy Network (BCAN) team, students also incorporated patient advocacy best practices into their submissions—ensuring that the patient voice is always kept top-of-mind throughout the drug development lifecycle.

THIS YEAR'S FINAL NOMINEES ARE...